Literature DB >> 24418358

Treatment of chronic hepatitis C virus infection in the United States: some remaining obstacles.

Gloria Searson1, Ellen S Engelson, Damaris Carriero, Donald P Kotler.   

Abstract

Hepatitis C infection is an important problem in inner city neighbourhoods, which suffer from multiple health disparities. Important factors in this population include alcoholism and substance abuse, mental illness and homelessness, which may be combined with mistrust, poor health literacy, limited access to healthcare and outright discrimination. Systemic barriers to effective care include a lack of capacity to provide comprehensive care, insufficient insurance coverage, poor coordination among caregivers and between caregivers and hospitals, as well as third party payers. These barriers affect real world treatment effectiveness as opposed to treatment efficacy, the latter reflecting the world of clinical trials. The components of effectiveness include efficacious medications, appropriate diagnosis and evaluation, recommendation for therapy, access to therapy, acceptance of the diagnosis and its implications by the patient and adherence to the recommended therapy. Very little attention has been given to assisting the patient to accept the diagnosis and adhere to therapy, i.e. care coordination. For this reason, care coordination is an area in which greater availability could lead to greater acceptance/adherence and greater treatment effectiveness.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alcoholism; chronic liver disease; effectiveness research; health disparities; substance abuse

Mesh:

Year:  2014        PMID: 24418358     DOI: 10.1111/liv.12467

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  6 in total

1.  Results from a Geographically Focused, Community-Based HCV Screening, Linkage-to-Care and Patient Navigation Program.

Authors:  Stacey B Trooskin; Joanna Poceta; Caitlin M Towey; Annajane Yolken; Jennifer S Rose; Najia L Luqman; Ta-Wanda L Preston; Philip A Chan; Curt Beckwith; Sophie C Feller; Hwajin Lee; Amy S Nunn
Journal:  J Gen Intern Med       Date:  2015-02-14       Impact factor: 5.128

2.  Barriers to Treatment Among New York City Residents with Chronic Hepatitis C Virus Infection, 2014.

Authors:  Andrea King; Katherine Bornschlegel; Nirah Johnson; Eric Rude; Fabienne Laraque
Journal:  Public Health Rep       Date:  2016 May-Jun       Impact factor: 2.792

Review 3.  Era of direct acting antivirals in chronic hepatitis C: Who will benefit?

Authors:  James Fung
Journal:  World J Hepatol       Date:  2015-10-28

4.  "Test, Listen, Cure" (TLC) Hepatitis C Community Awareness Campaign.

Authors:  Steven S Coughlin
Journal:  JMIR Res Protoc       Date:  2015-02-06

5.  Hepatitis C among blood donors: cascade of care and predictors of loss to follow-up.

Authors:  Soraia Mafra Machado; Cesar de Almeida; João Renato Rebello Pinho; Fernanda de Mello Malta; Ligia Capuani; Aléia Faustina Campos; Fatima Regina Marques Abreu; Ana Catharina de Seixas Santos Nastri; Rúbia Anita Ferraz Santana; Ester Cerdeira Sabino; Maria Cássia Mendes-Correa
Journal:  Rev Saude Publica       Date:  2017-04-27       Impact factor: 2.106

6.  Personality disorders do not affect treatment outcomes for chronic HCV infection in Spanish prisoners: the Perseo study.

Authors:  Andrés Marco; José J Antón; Joan Trujols; Pablo Saíz de la Hoya; José de Juan; Inmaculada Faraco; Joan A Caylà
Journal:  BMC Infect Dis       Date:  2015-08-19       Impact factor: 3.090

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.